Gupte Poonam Ashish, Mahajan Madhavi Prabhakar, Revadkar Kole Minakshi Subhash, Mandlecha Ajitkumar Harichand, Tatke Pratima Arun, Naharwar Vikram Andrew, Bhalerao Supriya Sudhakar
Department of Obesity Diabetes Laboratory, Interactive Research School For Health Affairs, Bharati Vidyapeeth (Deemed to be) University, Pune, Maharashtra, India.
Department of Kayachikitsa, College of Ayurved, Bharati Vidyapeeth (Deemed to be) University, Pune, Maharashtra, India.
Indian J Pharmacol. 2022 Jan-Feb;54(1):7-12. doi: 10.4103/ijp.ijp_914_20.
Acid peptic disorders.
This study aimed to assess the efficacy and acceptability of pomegranate effervescent granules (PEGs) in dyspeptic patients.
It was a single-arm, open-labeled prospective multicentric clinical study, done at 3 centers: Vishwanand Kendra, Pune; Bharati Ayurved Hospital, Bharati Vidyapeeth, Pune, and M. A. Podar Medical Ayurved Hospital, Mumbai. The co-ordinating site was Interactive Research School for Health Affairs, Bharati Vidyapeeth, Pune.
The granules, prepared from peel extract of pomegranate, were made available in sachets of 2.5 g with dose of, 1 sachet dissolved in 200 ml (1 cup) of water, twice a day after meals for 28 days. Gastrointestinal Symptom Rating Scale (GSRS) scores to assess symptoms of acid peptic disorders at day 0, 15, and 29 along with the taste of formulation were the main study outcomes.
Parametric data, presented as mean ± standard deviation, were analyzed using paired t-test, while nonparametric data presented as median (range) was analyzed using Wilcoxon rank-sum test. Categorical data were analyzed using Chi-square test.
The median GSRS score reduced from 14 on day 0-10 and then 5 on day 15 and day 29, respectively, with statistical significance. The formulation was found to taste good by ~80% of patients, while ~20% reported it to be palatable and none found it to be bad in taste.
PEGs proved to be palatable, patient-friendly, safe, and efficacious in resolving symptoms of dyspepsia in acid peptic disorders.
The trial was registered retrospectively in the Clinical Registry of India [CTRI/2017/07/008999].
酸相关性疾病。
本研究旨在评估石榴泡腾颗粒(PEGs)对消化不良患者的疗效和可接受性。
这是一项单臂、开放标签的前瞻性多中心临床研究,在3个中心进行:浦那的维什瓦南德中心;浦那巴拉蒂维迪佩特的巴拉蒂阿育吠陀医院;孟买的M.A.波达尔医学阿育吠陀医院。协调地点是浦那巴拉蒂维迪佩特的互动健康事务研究学院。
由石榴皮提取物制成的颗粒剂,每袋2.5克,剂量为1袋溶于200毫升(1杯)水中,每天饭后服用2次,共服用28天。主要研究结果是在第0天、第15天和第29天使用胃肠道症状评分量表(GSRS)评估酸相关性疾病的症状以及制剂的味道。
以均值±标准差表示的参数数据采用配对t检验进行分析,以中位数(范围)表示的非参数数据采用Wilcoxon秩和检验进行分析。分类数据采用卡方检验进行分析。
GSRS评分中位数从第0天至第10天的14降至第15天和第29天的5,具有统计学意义。约80%的患者认为该制剂味道良好,约20%的患者认为尚可接受,没有人认为味道不好。
PEGs在解决酸相关性疾病中的消化不良症状方面口感良好、对患者友好、安全且有效。
CTRI注册:该试验在印度临床注册中心进行了回顾性注册[CTRI/2017/07/008999]。